Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety

Patent metadata

Field	Value
Publication number	US-10004814-B2
Application number	US-201415035950-A
Country	US
Kind code	B2
Filing date	Nov 10, 2014
Priority date	Nov 11, 2013
Publication date	Jun 26, 2018
Grant date	Jun 26, 2018

Abstract

The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.

First claim

What is claimed is:

1. A double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of myostatin, wherein:
(a) the siNA comprises a sense strand and an antisense strand;
(b) each strand is independently 19 to 30 nucleotides in length; and
(c) the antisense strand comprises nucleotide sequence of:

(SEQ ID NO: 18)

5′- AUUAUUUGUUCUUUGCCAU -3′;

and wherein one or more of the nucleotides are chemically modified.

2. A double-stranded siNA molecule of claim 1 , wherein the siNA molecule comprises:

(SEQ ID NO: 1)

5′- AUGGCAAAGAACAAAUAAU -3′

and

(SEQ ID NO: 18)

5′- AUUAUUUGUUCUUUGCCAU -3′.

3. The double-stranded siNA molecule of claim 2 , wherein the siNA molecule is linked to a lipophilic moiety.

4. The double-stranded siNA molecule of claim 3 , wherein the lipophilic moiety is cholesterol.

5. The double-stranded siNA molecule of claim 4 , wherein the lipophilic moiety is attached to a 3′-end of the siNA molecule.

6. The double-stranded siNA molecule of claim 4 , wherein the lipophilic moiety is attached to a 5′-end of the siNA molecule.

7. The double-stranded siNA molecule of claim 2 , which comprises one or more chemically-modified nucleotides.

8. The double-stranded siNA molecule of claim 2 , which comprises one or more 3′-overhanging nucleotides on one or both strands.

9. The double-stranded siNA molecule of claim 1 , wherein the siNA molecule is linked to a lipophilic moiety.

10. The double-stranded siNA molecule of claim 9 , wherein the lipophilic moiety is cholesterol.

11. The double-stranded siNA molecule of claim 10 , wherein the lipophilic moiety is attached to a 3′-end of the siNA molecule.

12. The double-stranded siNA molecule of claim 10 , wherein the lipophilic moiety is attached to a 5′-end of the siNA molecule.

13. The double-stranded siNA molecule of claim 1 , which comprises one or more chemically-modified nucleotides.

14. The double-stranded siNA molecule of claim 1 , which comprises one or more 3′-overhanging nucleotides on one or both strands.

Assignees

• Sirna Therapeutics Inc
• Sepp Lorenzino Laura
• Jadhav Vasant
• Brown Duncan

Inventors

• Tadin-Strapps Marija
• Khan Tayeba
• Strapps Walter Richard
• Sepp-Lorenzino Laura
• Jadhav Vasant
• Brown Duncan

Classifications

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• A61K31/713 Primary

  Double-stranded nucleic acids or oligonucleotides · CPC title

• C12N2310/3515

  Lipophilic moiety, e.g. cholesterol · CPC title

• A61K48/0058 Primary

  Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct · CPC title